ArticleCancer immunology, immunotherapy : CII2016
Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155.
Article in Cancer immunology, immunotherapy : CII, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 69 citations in OpenAlex.
- Cytokine-induced killer (CIK) Cells-associated transcriptome signature reveals the potential immunomodulatory role of TNFSF14 in clear cell renal cell carcinoma.Cancer immunology, immunotherapy : CII · 2026Article
- CD96 marks a phenotypically distinct checkpoint-associated HCV-specific CD8+ T-cell subset featuring memory-associated states.Frontiers in immunology · 2026Article
- Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy.Cell communication and signaling : CCS · 2025Review
- Pan-cancer NK cell-related immunotherapy signatures for predicting PD-1 treatment response.Medicine · 2025Article
- Structure-guided engineering of CD112 receptor variants for optimized immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Pan-cancer analysis of co-inhibitory molecules revealing their potential prognostic and clinical values in immunotherapy.Frontiers in immunology · 2025Article
- Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families.Frontiers in immunology · 2025Review
- Emerging druggable targets for immune checkpoint modulation in cancer immunotherapy: the iceberg lies beneath the surface.Apoptosis : an international journal on programmed cell death · 2024Review
- The emerging role of Fusobacteria in carcinogenesis.European journal of clinical investigation · 2024Review
- Exploring the role of Fusobacterium nucleatum in colorectal cancer: implications for tumor proliferation and chemoresistance.Cell communication and signaling : CCS · 2024Review
- Natural Killer Cells in Cancers of Respiratory System and Their Applications in Therapeutic Approaches.Immunity, inflammation and disease · 2024Review
- Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.Journal of clinical medicine · 2024Review
- Immune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling.Cancers · 2024Review
- Targeting TIGIT for cancer immunotherapy: recent advances and future directions.Biomarker research · 2024Review
- The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy.Frontiers in immunology · 2024Review
- Lineage origin and transcriptional control of autoantigen-specific T-regulatory type 1 cells.Frontiers in immunology · 2023Review
- Review
- Review
- DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy.Clinical epigenetics · 2022Article
- Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis.Cancer immunology, immunotherapy : CII · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T cell Ig and ITIM domain (TIGIT) is a newly identified inhibitory receptor expressed on T and natural killer (NK) cells. Cytokine-induced killer (CIK) cells express CD3 and CD56 molecules, and share functional properties with both NK and T cells. However, it remains unknown whether TIGIT is expressed in CIK cells. Here, we show that TIGIT is expressed by CIK cells and interacts with CD155. By blocking TIGIT using an anti-TIGIT functional antibody, we demonstrate that CIK cells display increased proliferation; higher cytotoxic targeting of tumor cells expressing CD155; and higher expression of interferon-γ (IFN-γ), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Furthermore, increases in IFN-γ and cytotoxicity by blockade of TIGIT were reduced by blocking DNAX accessory molecule-1 (DNAM-1) signaling, implying that TIGIT exerts immunosuppressive effects by competing with DNAM-1 for the same ligand, CD155. Our results provide evidence that blockade of TIGIT may be a novel strategy to improve the cytotoxic activity of CIK cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.